Sign inJoin waitlistJoin the waitlist

MB

Melissa Burgess

Physician · Upmc

Credentials: · · ·

History

Upmc
Present

University of Pittsburgh
2012–2015
Internal Medicine
UPMC Medical Education
2009–2012
Doctor of Medicine
2005–2009

Research

B cells are associated with survival and immunotherapy response in sarcoma
Nature · 2020 · 1,598 citations
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,203 citations
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Journal of Clinical Oncology · 2019 · 300 citations

Steven Attia
9 papers
BT
Brian Van Tine
8 papers
Hussein Tawbi
8 papers
Richard Riedel
8 papers
SS
Scott Schuetze
7 papers
Ivy John
6 papers
Scott Okuno
6 papers
Gary Schwartz
5 papers
HD
Hari Deshpande
5 papers
Alexander Lazar
4 papers · 2 as a fellow
ES
Elad Sharon
4 papers
Elizabeth Davis
4 papers

Clinical trials

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Principal investigator · Terminated · Phase 2
Melissa Burgess, MD
2015–2016
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
Principal investigator · Completed · Phase 1, Phase 2
Melissa Burgess, MD
2013–2021
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Site PI · Recruiting · Phase 2, Phase 3
TuHURA Biosciences, Inc.
2025–2032
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030